Bluebird Bio Inc. (NASDAQ:BLUE) shares shot up 5.2% on Wednesday . The company traded as high as $58.27 and last traded at $58.27, with a volume of 462,318 shares changing hands. The stock had previously closed at $55.41.

Several brokerages have commented on BLUE. Zacks Investment Research downgraded Bluebird Bio from a “hold” rating to a “sell” rating in a research report on Monday, May 2nd. Cantor Fitzgerald began coverage on Bluebird Bio in a research report on Thursday, June 2nd. They issued a “hold” rating and a $42.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $117.00 price target on shares of Bluebird Bio in a research report on Thursday, May 5th. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $117.00 price target on shares of Bluebird Bio in a research report on Wednesday, May 11th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Bluebird Bio in a research report on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company. Bluebird Bio currently has an average rating of “Buy” and a consensus target price of $96.09.

The stock’s 50-day moving average is $46.24 and its 200 day moving average is $45.67. The firm’s market capitalization is $2.19 billion.

Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings data on Thursday, August 4th. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.15. The business earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. During the same quarter last year, the company earned ($1.57) EPS. The firm’s revenue for the quarter was down 68.6% on a year-over-year basis. Analysts expect that Bluebird Bio Inc. will post ($5.90) earnings per share for the current year.

In other news, insider David Davidson sold 1,000 shares of the stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $38.73, for a total transaction of $38,730.00. Following the transaction, the insider now owns 10,600 shares in the company, valued at $410,538. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Philip D. Gregory sold 2,931 shares of the stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $39.52, for a total value of $115,833.12. Following the transaction, the insider now owns 30,069 shares in the company, valued at approximately $1,188,326.88. The disclosure for this sale can be found here.

Other institutional investors have recently made changes to their positions in the company. RS Investment Management Co. LLC raised its position in shares of Bluebird Bio by 91.6% in the fourth quarter. RS Investment Management Co. LLC now owns 515,846 shares of the company’s stock worth $33,128,000 after buying an additional 246,622 shares during the period. State of Tennessee Treasury Department raised its position in shares of Bluebird Bio by 45.4% in the fourth quarter. State of Tennessee Treasury Department now owns 191,963 shares of the company’s stock worth $12,328,000 after buying an additional 59,952 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Bluebird Bio by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 74,831 shares of the company’s stock worth $4,806,000 after buying an additional 4,454 shares during the period. Jennison Associates LLC raised its position in shares of Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock worth $55,506,000 after buying an additional 545,727 shares during the period. Finally, Marshall Wace LLP raised its position in shares of Bluebird Bio by 374.8% in the fourth quarter. Marshall Wace LLP now owns 168,427 shares of the company’s stock worth $10,816,000 after buying an additional 132,956 shares during the period.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.